ARP Americas LP Sells 2,642 Shares of PRA Health Sciences Inc (NASDAQ:PRAH)

ARP Americas LP lowered its holdings in PRA Health Sciences Inc (NASDAQ:PRAH) by 44.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,257 shares of the medical research company’s stock after selling 2,642 shares during the quarter. ARP Americas LP’s holdings in PRA Health Sciences were worth $317,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. State of Michigan Retirement System grew its holdings in PRA Health Sciences by 32.6% in the 2nd quarter. State of Michigan Retirement System now owns 23,197 shares of the medical research company’s stock valued at $2,257,000 after buying an additional 5,697 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of PRA Health Sciences by 45.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,306 shares of the medical research company’s stock worth $711,000 after purchasing an additional 2,271 shares in the last quarter. NN Investment Partners Holdings N.V. grew its holdings in shares of PRA Health Sciences by 1.9% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 1,467,552 shares of the medical research company’s stock worth $142,778,000 after purchasing an additional 26,756 shares in the last quarter. Dupont Capital Management Corp grew its holdings in shares of PRA Health Sciences by 191.1% during the 2nd quarter. Dupont Capital Management Corp now owns 13,491 shares of the medical research company’s stock worth $1,313,000 after purchasing an additional 8,857 shares in the last quarter. Finally, Strs Ohio grew its holdings in shares of PRA Health Sciences by 101.5% during the 2nd quarter. Strs Ohio now owns 15,828 shares of the medical research company’s stock worth $1,539,000 after purchasing an additional 7,974 shares in the last quarter. 98.15% of the stock is currently owned by hedge funds and other institutional investors.

PRAH traded down $0.19 during trading on Friday, hitting $106.56. The company’s stock had a trading volume of 252,209 shares, compared to its average volume of 223,702. The firm’s 50 day moving average price is $97.98 and its two-hundred day moving average price is $95.54. The company has a quick ratio of 0.93, a current ratio of 0.93 and a debt-to-equity ratio of 1.14. PRA Health Sciences Inc has a 12 month low of $58.67 and a 12 month high of $113.32. The stock has a market capitalization of $6.79 billion, a price-to-earnings ratio of 23.37 and a beta of 1.10.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.01 by $0.04. PRA Health Sciences had a return on equity of 27.59% and a net margin of 7.66%. The firm had revenue of $783.71 million during the quarter, compared to the consensus estimate of $749.61 million. During the same quarter in the previous year, the company posted $1.10 EPS. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, sell-side analysts forecast that PRA Health Sciences Inc will post 3.7 earnings per share for the current year.

Several analysts have recently weighed in on the company. SunTrust Banks lifted their price objective on PRA Health Sciences from $89.00 to $103.00 and gave the stock a “buy” rating in a report on Monday, May 4th. Credit Suisse Group decreased their price objective on PRA Health Sciences from $122.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, May 1st. William Blair lowered PRA Health Sciences from an “outperform” rating to a “market perform” rating in a report on Friday, May 1st. Wolfe Research downgraded PRA Health Sciences from an “outperform” rating to a “market perform” rating and set a $97.00 target price for the company. in a research report on Monday, April 13th. Finally, Zacks Investment Research upgraded PRA Health Sciences from a “sell” rating to a “hold” rating and set a $99.00 target price for the company in a research report on Tuesday, May 19th. Seven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $100.82.

PRA Health Sciences Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Read More: What is a bull market?

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.